Dendreon Set To Ship Provenge Within A Week
This article was originally published in The Pink Sheet Daily
Executive Summary
Demand expected to exceed supply as company builds manufacturing capacity.
You may also be interested in...
Merck & Co. Pounces On Moderna mRNA-Based Cancer Vaccine Option
The company will pay Moderna $250m upfront to develop and commercialize a personalized cancer vaccine for melanoma in combination with Keytruda.
Remember When Provenge's Price Was Bold? Every New Cancer Drug In 2017 Cost $100,000 Or More
The price of new oncology brands doubled in the US from 2013 to 2017, bringing the median annual price to more than $160,000 last year, up from $79,000 in 2013, according to a new IQVIA report. Spending on cancer drugs in the US has doubled since 2012, reaching nearly $50bn in 2017.
Deal Watch: Valeant’s Financial/Commercial Strength Offers A New Chance For Provenge
AstraZeneca buys out respiratory franchise from Actavis, which it had gained a year prior with its purchase of Forest. Mylan announced two deals Feb. 2, collaborating in COPD with Theravance and buying women’s health products from India’s Famy Care.